EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction

Yusuke Inoue, Hirofumi Tenshin, Jumpei Teramachi, Ryohei Sumitani, Asuka Oda, Yusaku Maeda, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura und 8 weitere

Cancer Science · 2025-02 · 116 (2) · 559-563

DOI: 10.1111/cas.16401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 18.11.2024. Verfasst von Yusuke Inoue und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, Tokushima University Hospital, Tokushima, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Osteoclasts, Antibodies, Monoclonal, Humanized, Antibody-Dependent Cell Cytotoxicity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Research Clusters program of Tokushima University, Japanese Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) cells and osteoclasts (OCs) activate with each other to cause drug resistance. Human Th1‐like Vγ9Vδ2 (γδ) T cells, important effectors against tumors, can be expanded and activated ex vivo by the aminobisphosphonate zoledronic acid in combination with IL‐2. We previously reported that the expanded γδ T cells effectively targeted and killed OCs as well as MM cells. Because the expanded γδ T cells expressed CD16 on their surface, we investigated the utilization of the expanded γδ T cells for antibody‐dependent cellular cytotoxicity (ADCC). Although the expanded γδ T cells alone induced cell death in MM cell lines, the addition of the anti‐SLAMF7 monoclonal antibody elotuzumab (ELO) further enhanced their cytotoxic activity only against SLAMF7‐expressing MM cell lines and primary MM cells. Intriguingly, ELO was also able to enhance γδ T cell‐induced cell death against OCs cultured alone, and against both MM cells and OCs in their coculture settings. SLAMF7 was found to be highly expressed in OCs differentiated in vitro from monocytes by receptor activator of nuclear factor‐κ B ligand and M‐CSF, although monocytes only marginally expressed SLAMF7. These results demonstrate that SLAMF7 is highly expressed in both MM cells and OCs, and that the ex vivo‐expanded γδ T cells can exert ELO‐mediated ADCC against SLAMF7‐expressing MM cells and OCs besides their direct cytotoxic activity. Further study is warranted for the innovative utilization of γδ T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaOsteoclastsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityTh1 CellsHumansReceptors, Antigen, T-Cell, gamma-deltaCell Line, TumorSignaling Lymphocytic Activation Molecule FamilyZoledronic AcidCoculture TechniquesDiphosphonatesIntraepithelial LymphocytesInterleukin-2

Stichwörter der Autor:innen

ElotuzumabSLAMF7Vγ9Vδ2 T cellmultiple myelomaosteoclast

Substanzen

Antibodies, Monoclonal, HumanizedelotuzumabSLAMF7 protein, humanReceptors, Antigen, T-Cell, gamma-deltaSignaling Lymphocytic Activation Molecule FamilyZoledronic AcidDiphosphonatesInterleukin-2

Autor:innen und Institutionen

  • Department of Medical Technology, Tokushima University Hospital, Tokushima, Japan.
  • Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan.

ORCID-Profile: Takeshi Harada

Förderung

  • Japan Society for the Promotion of Science
  • Research Clusters program of Tokushima University
  • Japanese Society of Hematology
  • Bristol Myers Squibb Foundation

Zitieren

APA

Inoue, Y., Tenshin, H., Teramachi, J., Sumitani, R., Oda, A., Maeda, Y., Oura, M., Sogabe, K., Maruhashi, T., Takahashi, M., Fujii, S., Nakamura, S., Miki, H., Hara, T., Endo, I., Kagawa, K., Ozaki, S., Hiasa, M., Harada, T., & Abe, M. (2025). Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction. Cancer Science, 116(2), 559-563. https://doi.org/10.1111/cas.16401

Vancouver

Inoue Y, Tenshin H, Teramachi J, Sumitani R, Oda A, Maeda Y, et al. Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction. Cancer Science. 2025;116(2):559-563. doi:10.1111/cas.16401

BibTeX
@article{Inoue2025,
  author = {Inoue, Yusuke and Tenshin, Hirofumi and Teramachi, Jumpei and Sumitani, Ryohei and Oda, Asuka and Maeda, Yusaku and Oura, Masahiro and Sogabe, Kimiko and Maruhashi, Tomoko and Takahashi, Mamiko and Fujii, Shiro and Nakamura, Shingen and Miki, Hirokazu and Hara, Tomoyo and Endo, Itsuro and Kagawa, Kumiko and Ozaki, Shuji and Hiasa, Masahiro and Harada, Takeshi and Abe, Masahiro},
  title = {Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {2},
  pages = {559--563},
  doi = {10.1111/cas.16401}
}
Kostenlos starten →